secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-046852
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo receives $69.4M from full warrant exercise; cash runway into at least 2027
--------------------------------------------------------------------------------

- Gross proceeds of $69.4M from exercise of 11,967,526 warrants at $5.796933/share; total private placement proceeds now $185M.
- Cash runway expected into at least 2027, funding Phase 2 LOTUS trial and expansion of AVTX-009 program.
- As of Nov 8, 2024: 10,463,633 common shares outstanding; 24,895.92 Series C Preferred shares convertible into 24.9M common shares subject to ownership limits.
- CEO states focus on hidradenitis suppurativa trial and identifying next inflammatory indication for AVTX-009.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024046852/0001628280-24-046852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828024046852/avtx-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer